Diabetes: Page 6

  • A person sits in front of a plate of food, holding a smartphone. They're wearing a patch on their left arm.
    Image attribution tooltip
    Courtesy of Insulet Corp.
    Image attribution tooltip

    Insulet wins CE mark for integration of insulin pump with Abbott CGM

    The clearance positions Insulet to sell the integrated Type 1 diabetes product in Europe beginning in the first half of the year.

    By • Feb. 8, 2024
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA extends deadline for comments on role of digital health in diabetes detection

    The agency is seeking answers on how digital health technologies could be used in the detection of prediabetes and Type 2 diabetes.

    By • Jan. 31, 2024
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline➔
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • Abbott Laboratories
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott says all four segments stronger than pre-pandemic

    CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”

    By • Jan. 24, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    3 bellwether companies to watch as medtech earnings season begins

    J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.

    By • Jan. 22, 2024
  • A smartphone screen reads "Your glucose is steady. Grab a leafy green snack to maintain momentum."
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip

    Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference

    CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.

    By • Jan. 10, 2024
  • Professional photo of Geoff Martha
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic focused on delivering durable revenue and profit growth

    “Our top priority is restoring our earnings power, full stop,” CEO Geoff Martha said Monday at the J.P. Morgan Healthcare Conference.

    By • Jan. 9, 2024
  • Professional photo of Kevin Sayer
    Image attribution tooltip
    Permission granted by Dexcom
    Image attribution tooltip

    Dexcom plans to launch new CGM this summer for people who don’t take insulin

    The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.

    By • Jan. 9, 2024
  • A person smiles while wearing a square device on their hip and a round device on their upper arm.
    Image attribution tooltip
    Courtesy of Tandem Diabetes Care
    Image attribution tooltip

    Abbott, Tandem launch new hybrid closed-loop insulin delivery system

    Competitor Medtronic also received a CE mark for a new CGM sensor that can integrate with its 780G pump.

    By • Jan. 8, 2024
  • An embpty bed is surrounded by monitors and hospital equipment.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’

    Rising interest rates, fears about the impact of GLP-1 drugs and “choppy supply-chain dynamics” dragged on the industry this year, the analysts wrote.

    By • Dec. 18, 2023
  • A person types on a computer with a stethoscope in the background.
    Image attribution tooltip
    Courtesy of Tandem Diabetes Care
    Image attribution tooltip

    Tandem completes US launch of revamped diabetes management platform

    The platform, Tandem Source, combines the features of the company’s legacy t:connect offerings with new data reports.

    By • Dec. 15, 2023
  • From left to right: A white, rectangular device that says "EO," a black device with a screen that says "EOWatch," and a smartphone.
    Image attribution tooltip
    Courtesy of EOFlow
    Image attribution tooltip

    Medtronic scraps plans to buy insulin patch-pump maker EOFlow

    Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.

    By • Dec. 7, 2023
  • Nick Jonas, Dexcom
    Image attribution tooltip
    Courtesy of Dexcom, Nick Jonas Super Bowl kit
    Image attribution tooltip

    Dexcom, Hologic picked to outperform in 2024: William Blair

    For the medtech industry overall, the analysts wrote that procedure volume growth is likely to normalize after declining due to the COVID-19 pandemic.

    By • Dec. 7, 2023
  • the FDA Headquarters
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip

    Unomedical recall of infusion sets tagged as Class I by FDA

    The company notified Tandem Diabetes Care, its sole consignee, in October of the risk for infusion sets to detach from insulin pumps, disrupting insulin delivery.

    By • Nov. 28, 2023
  • Professional photo of Dev Kurdikar
    Image attribution tooltip
    Permission granted by Embecta
    Image attribution tooltip
    Q&A

    Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s

    The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.

    By • Nov. 21, 2023
  • People walk around a vertical screen that reads "Every 23 Seconds"
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip
    Q&A

    Abbott Diabetes Care CMO Mahmood Kazemi on expanding CGM access

    Kazemi hopes anyone with diabetes will be able to access the technology, even people who don’t take insulin.

    By • Nov. 17, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Wegovy study details revive debate over GLP-1 impact on devices

    The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.

    By • Nov. 13, 2023
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

    The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.

    By • Nov. 9, 2023
  • A smartphone on the left shows time in range, and a small, square device on the right is compared to a quarter in size.
    Image attribution tooltip
    Courtesy of Tandem
    Image attribution tooltip

    Diabetes tech firms focusing on Type 2 patients

    Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

    By • Nov. 7, 2023
  • A building in front of a pond with the sign "Medtronic" on a stone wall.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    5 companies to watch as medtech earnings wind down

    Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

    By • Nov. 6, 2023
  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Drilling down on obesity drugs: What medtech executives are saying

    Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

    By • Nov. 2, 2023
  • An artificial intelligence processor unit
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GE HealthCare’s imaging AI will become ‘increasingly meaningful’ to growth: Moody’s

    Even if modestly accretive, AI could support longer-term revenue targets at GE HealthCare and its competitors, Moody’s analysts wrote.

    By • Oct. 27, 2023
  • A person looks at a black and white image on a screen as they hold an ultrasound device to another person's chest.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GE HealthCare, Novo Nordisk partner to use ultrasound to treat diabetes, obesity

    The collaborators will study the use of peripheral focused ultrasound as a non-invasive, non-pharmacological method of managing blood glucose.

    By • Oct. 25, 2023
  • A person sits in front of a plate of food, holding a smartphone. They're wearing a patch on their left arm.
    Image attribution tooltip
    Courtesy of Insulet Corp.
    Image attribution tooltip

    Insulet receives FDA clearance for Omnipod 5 iPhone app

    The application removes the need for patients with iPhones to carry a separate controller to manage bolus dosing.

    By • Oct. 23, 2023
  • Abbott FreeStyle Libre 3 sensor
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott raises outlook amid strong Q3, sees momentum into 2024

    Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.

    By • Oct. 18, 2023
  • Close-up of a sign with office building and trees in background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Boston Scientific wins diabetic neuropathy approval, joining rivals in growing market

    The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.

    By • Oct. 12, 2023